Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential

Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech

Lifeward acquires Oramed’s clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportunity

POD™ targets the $600+ billion injectable drugs market, including ORMD-0801, which has the potential to become the world’s first commercialized oral insulin medicine

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) –…